首站-论文投稿智能助手
典型文献
Therapeutic potential of colchicine in cardiovascular medicine:a pharmacological review
文献摘要:
Colchicine is an ancient herbal drug derived from Colchicum autumnale.It was first used to treat familial Mediterranean fever and gout.Based on its unique efficacy as an anti-inflammatory agent,colchicine has been used in the therapy of cardiovascular diseases including coronary artery disease,atherosclerosis,recurrent pericarditis,vascular restenosis,heart failure,and myocardial infarction.More recently,colchicine has also shown therapeutic efficacy in alleviating cardiovascular complications of COVID-19.COLCOT and LoDoCo2 are two milestone clinical trials that confirm the curative effect of long-term administration of colchicine in reducing the incidence of cardiovascular events in patients with coronary artery disease.There is growing interest in studying the anti-inflammatory mechanisms of colchicine.The anti-inflammatory action of colchicine is mediated mainly through inhibiting the assembly of microtubules.At the cellular level,colchicine inhibits the following:(1)endothelial cell dysfunction and inflammation;(2)smooth muscle cell proliferation and migration;(3)macrophage chemotaxis,migration,and adhesion;(4)platelet activation.At the molecular level,colchicine reduces proinflammatory cytokine release and inhibits NF-KB signaling and NLRP3 inflammasome activation.In this review,we summarize the current clinical trials with proven curative effect of colchicine in treating cardiovascular diseases.We also systematically discuss the mechanisms of colchicine action in cardiovascular therapeutics.Altogether,colchicine,a bioactive constituent from an ancient medicinal herb,exerts unique anti-inflammatory effects and prominent cardiovascular actions,and will charter a new page in cardiovascular medicine.
文献关键词:
作者姓名:
Fan-shun Zhang;Qing-ze He;Chengxue Helena Qin;Peter J.Little;Jian-ping Weng;Suo-wen Xu
作者机构:
Institute of Endocrine and Metabolic Diseases,The First Affiliated Hospital of USTC,Division of Life Science and Medicine,University of Science and Technology of China,Hefei 230001,China;Faculty of Pharmacy and Pharmaceutical Sciences,Monash Institute of Pharmaceutical Sciences,Monash University(Parkville Campus),381 Royal Parade,Parkville 3052 VIC,Australia;Sunshine Coast Health Institute,University of the Sunshine Coast,Birtinya 4575 QLD,Australia;School of Pharmacy,The University of Queensland,Woolloongabba 4102 QLD,Australia;Biomedical Sciences and Health Laboratory of Anhui Province,University of Science&Technology of China,Hefei 230027,China
引用格式:
[1]Fan-shun Zhang;Qing-ze He;Chengxue Helena Qin;Peter J.Little;Jian-ping Weng;Suo-wen Xu-.Therapeutic potential of colchicine in cardiovascular medicine:a pharmacological review)[J].中国药理学报(英文版),2022(09):2173-2190
A类:
Colchicine,Colchicum,autumnale,COLCOT,LoDoCo2,charter
B类:
Therapeutic,potential,colchicine,cardiovascular,medicine,pharmacological,review,ancient,herbal,drug,derived,from,It,was,first,used,familial,Mediterranean,fever,gout,Based,unique,efficacy,anti,agent,has,been,therapy,diseases,including,coronary,artery,atherosclerosis,recurrent,pericarditis,restenosis,heart,failure,myocardial,infarction,More,recently,also,shown,alleviating,complications,are,two,milestone,clinical,trials,that,confirm,curative,long,term,administration,reducing,incidence,events,patients,There,growing,interest,studying,mechanisms,mediated,mainly,through,inhibiting,assembly,microtubules,At,cellular,level,inhibits,following,endothelial,dysfunction,inflammation,smooth,muscle,proliferation,migration,macrophage,chemotaxis,adhesion,platelet,activation,molecular,reduces,proinflammatory,cytokine,release,KB,signaling,NLRP3,inflammasome,In,this,we,summarize,proven,treating,We,systematically,discuss,therapeutics,Altogether,bioactive,constituent,medicinal,exerts,effects,prominent,actions,will,new,page
AB值:
0.549666
相似文献
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD:A promising drug Potentilla discolor Bunge
Longshan Ji;Qian Li;Yong He;Xin Zhang;Zhenhua Zhou;Yating Gao;Miao Fang;Zhuo Yu;Robim M.Rodrigues;Yueqiu Gao;Man Li-Laboratory of Cellular Immunity,Institute of Clinical Immunology,Shanghai Key Laboratory of Traditional Chinese Medicine,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Key Laboratory of Liver and Kidney Diseases(Shanghai University of Traditional Chinese Medicine),Ministry of Education,Shanghai 201203,China;Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Department of Hepatopathy,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of in Vitro Toxicology and Dermato-Cosmetology,Faculty of Medicine and Pharmacy,Vrije Universiteit Brussel,Brussels 1000,Belgium
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。